SACRAMENTO, California, September 17 /PRNewswire/ --     
In the news release, "New Orthopedic Surgical Robotics Company Opens Its 
Doors; Files with the FDA for Clearance of Its Flagship Product" issued on 
17 Sep 2007 01:09 GMT, by Curexo, Inc.  over PR Newswire, we are advised by 
a representative of the company that in the first paragraph, the word 
"Services" should be "Systems". Complete, corrected release follows:



- Computer Assisted Surgery at the Forefront

Novatrix Biomedical, Inc. announced today that it has formed a new 
company, Curexo Medical, Inc. (CMI), with the acquisition of all assets of 
Integrated Surgical Systems, Inc. (ISS). Under the licensing agreement, 
Curexo, Inc., will transfer all the assets acquired from ISS to CMI.

Curexo Medical, Inc., located in Sacramento, California, retained the
former officers and employees of ISS in order to facilitate rapid
introduction of its surgical robotics system into the U.S. orthopedic market.
The system is called ROBODOC(R) Surgical Assistant System (the ROBODOC). The
ROBODOC has been very well received by hospitals and orthopedic surgeons from
both academic institutions and private hospitals in Europe and Asia,
including Japan, Korea and India. The system has already been approved by
Korea's regulatory agency, KFDA.

"CMI's mission is to make computer assisted surgery a gold standard for
all major orthopedic surgeries by the year 2012 and to be the world leader in
this market segment," said Dr. Ramesh Trivedi, President and CEO.

"We have already received funding from Novatrix and have been assured of
future funding to accomplish our goals," said Trivedi. "We are actively
recruiting highly qualified and experienced staff to rapidly grow the
business."

Novatrix Biomedical, Inc., based in Southern California, develops
proprietary technologies in the drug delivery field. "We firmly believe that
CMI has the right strategy, a well thought out plan and a highly experienced
team in place to be a dominant player in the orthopedic surgical robotics
field," said Dr. Soon Kap Hahn, President and CEO of Novatrix Biomedical.

"Along with our partner, Curexo Inc., Korea, we are committed to fund CMI
to secure U.S. Food and Drug Administration (FDA) clearance, enter the U.S.
market and continue building the ongoing business in other major markets of
the world."

Curexo Medical, Inc. also announced that it has submitted a 510(k)
pre-market notification to the U.S. FDA for the clearance of its ROBODOC
Surgical Assistance System for marketing in the U.S. A 90-day period is
customary for FDA review of a 510(k) submission.

http://www.robodoc.com

Contact:                             Media Contact
    Dr. Ramesh C. Trivedi                Tami Adachi
    President & CEO                      +1-415-370-9638
    Curexo Medical, Inc.                 tadachi@mindspring.com
    +1-916-285-9943, X511



Web site: http://www.robodoc.com